rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients

Objective. Increased viscosity may increase the risk of thrombosis or thromboembolic events. Recombinant human erythropoietin (rHuEPO) is the key stone treatment in anemic ESRD patients with the thrombotic limiting side effect. We evaluated the influence of clinical and laboratory findings on plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Erkmen Uyar, Mehtap, Toprak, Selami Kocak, Saglam, Hatice, Tutal, Emre, Bay, Meltem, Ilhan, Osman, Bal, Zeynep, Sezer, Siren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806397/
https://www.ncbi.nlm.nih.gov/pubmed/24198729
http://dx.doi.org/10.1155/2013/792698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806397/
https://www.ncbi.nlm.nih.gov/pubmed/24198729
http://dx.doi.org/10.1155/2013/792698

Ejemplares similares